A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
- Status
- RECRUITING
- Phase
- NA
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
- Status
- RECRUITING
- Phase
- PHASE3
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
- Status
- RECRUITING
- Phase
- PHASE3
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
- Status
- RECRUITING
- Phase
- PHASE3
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome
- Status
- COMPLETED
- Phase
- NA
Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2